RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Iterum Therapeutics - Stock

Iterum Therapeutics P/S 2024

Iterum Therapeutics P/S

0

Iterum Therapeutics Dividend yield

Ticker

ITRM

ISIN

IE00BF3W0Q35

WKN

A2JMZP

As of Jun 6, 2024, Iterum Therapeutics's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Iterum Therapeutics P/S history

Iterum Therapeutics Aktienanalyse

What does Iterum Therapeutics do?

Iterum Therapeutics is an Irish biotechnology company that focuses on developing antibiotics for serious bacterial infections. The company was founded in 2015 and has since undergone several successful financing rounds. The business model of Iterum Therapeutics is based on the discovery, development, and commercialization of novel anti-infectives that specialize in hard-to-reach or resistant bacteria. The company has developed a strong pipeline of antibiotic products that aim to combat the growing threat of antibiotic resistance. Iterum Therapeutics operates in several sectors, including clinical development, manufacturing, and marketing of antibiotic products. The company collaborates with leading industry players to ensure the effectiveness and safety of its products. One of Iterum Therapeutics' products is Sulopenem, a novel antibiotic specifically developed for treating infections caused by various types of bacteria. Sulopenem has shown promise in clinical studies and has the potential to play a significant role in combating antibiotic resistance. In addition, Iterum Therapeutics is also developing other antibiotic products focusing on combating bacteria responsible for severe infections, including Pseudomonas aeruginosa and Enterobacteriaceae. Iterum Therapeutics has a strong research and development department that focuses on the discovery and development of new antibiotic products. The company works closely with leading universities and research institutions to build a strong pipeline of innovative anti-infectives. The products of Iterum Therapeutics have the potential to make a significant contribution to combating antibiotic resistance and serious infections. The company is committed to further advancing the growth of its pipeline and maximizing the potential of its products to improve the health of patients worldwide. Iterum Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Iterum Therapeutics's P/S Ratio

Iterum Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Iterum Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Iterum Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Iterum Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Iterum Therapeutics Stock

What is the price-to-earnings ratio of Iterum Therapeutics?

The price-earnings ratio of Iterum Therapeutics is currently 0.

How has the price-earnings ratio of Iterum Therapeutics changed compared to last year?

The price-to-earnings ratio of Iterum Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Iterum Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Iterum Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Iterum Therapeutics affect the company?

An increase in the price-earnings ratio of Iterum Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Iterum Therapeutics affect the company?

A decrease in the price-earnings ratio of Iterum Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Iterum Therapeutics?

Some factors that influence the price-earnings ratio of Iterum Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Iterum Therapeutics pay?

Over the past 12 months, Iterum Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Iterum Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Iterum Therapeutics?

The current dividend yield of Iterum Therapeutics is .

When does Iterum Therapeutics pay dividends?

Iterum Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Iterum Therapeutics?

Iterum Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Iterum Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Iterum Therapeutics located?

Iterum Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Iterum Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Iterum Therapeutics from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Iterum Therapeutics pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Iterum Therapeutics in the year 2023?

In the year 2023, Iterum Therapeutics distributed 0 USD as dividends.

In which currency does Iterum Therapeutics pay out the dividend?

The dividends of Iterum Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Iterum Therapeutics

Our stock analysis for Iterum Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Iterum Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.